Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) Sees Significant Increase in Short Interest

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) saw a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 146,438 shares, an increase of 3,848.2% from the June 30th total of 3,709 shares. Based on an average daily trading volume, of 50,488 shares, the short-interest ratio is presently 2.9 days.

Rocket Pharmaceuticals Stock Down 10.0%

NASDAQ:RCKTW traded down $0.00 during trading hours on Friday, reaching $0.00. 4,061 shares of the company’s stock were exchanged, compared to its average volume of 29,443. The company has a 50-day moving average of $0.01 and a 200 day moving average of $0.01. Rocket Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $0.08.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.

Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW.